RxDoctor Payments Data

Frank Slovick, MD

Hematology & Oncology · Kansas City, MONPI 1609869007

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (36.7%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by GSK at 36.7% of the total. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.

$1,173in general payments, 2019–2025

Across 18 payments — averaging $65.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$430
  • Johnson & Johnson$289
  • Foundation Medicine, Inc.$202
  • Gilead$118
  • Sanofi$69
  • Acrotech Biopharma Inc.$26
  • plus $39 from 2 others
$60,106in research payments, 2019–2025

Across 8 payments — averaging $7513.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$60K

What the payments were for

  • Consulting fees$43037%
  • Speaking & faculty fees$20217%
  • Food & beverage$41635%
  • Education$12511%

General payments by program year

19
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,173 in reported general payments places this provider in the 45th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$11,358
Medicare patients
61
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →